Sanford C. Bernstein set a €123.00 ($151.85) price objective on Bayer (FRA:BAYN) in a research note issued to investors on Friday morning. The brokerage currently has a buy rating on the healthcare company’s stock.
Several other equities research analysts have also recently issued reports on the stock. Barclays set a €100.00 ($123.46) target price on shares of Bayer and gave the stock a sell rating in a research report on Tuesday, December 12th. UBS set a €125.00 ($154.32) target price on shares of Bayer and gave the stock a buy rating in a research report on Thursday, December 7th. Goldman Sachs set a €125.00 ($154.32) target price on shares of Bayer and gave the stock a buy rating in a research report on Tuesday, January 23rd. JPMorgan Chase set a €128.00 ($158.02) target price on shares of Bayer and gave the stock a buy rating in a research report on Friday, December 29th. Finally, Citigroup reissued a buy rating on shares of Bayer in a research report on Friday, February 16th. One analyst has rated the stock with a sell rating, seven have issued a hold rating and fifteen have issued a buy rating to the company’s stock. The stock has an average rating of Buy and a consensus price target of €118.05 ($145.74).
BAYN opened at €93.49 ($115.42) on Friday. Bayer has a 1 year low of €91.58 ($113.06) and a 1 year high of €123.82 ($152.86).
TRADEMARK VIOLATION WARNING: “Sanford C. Bernstein Analysts Give Bayer (BAYN) a €123.00 Price Target” was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are accessing this piece of content on another site, it was stolen and reposted in violation of United States & international trademark and copyright legislation. The legal version of this piece of content can be read at https://www.dispatchtribunal.com/2018/04/09/sanford-c-bernstein-analysts-give-bayer-bayn-a-123-00-price-target.html.
Bayer Company Profile
Bayer Aktiengesellschaft operates as a life science company worldwide. The company operates through Pharmaceuticals, Consumer Health, Crop Science, Animal Health, and Covestro segments. The Pharmaceuticals segment offers prescription products primarily for cardiology and women's health care; specialty therapeutics in the areas of oncology, hematology, and ophthalmology; and diagnostic imaging equipment and contrast agents.
Receive News & Ratings for Bayer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bayer and related companies with MarketBeat.com's FREE daily email newsletter.